Cell and Gene Therapy Manufacturing Services Market Size & Opportunities Analysis - Growth Strategies, Competitiveness, and Forecasts (2025 - 2032)

Cell and Gene Therapy Manufacturing Services Market Growth Factors

Increasing Outsourcing Activities Are Biggest Trend

The complex and specialized nature of cell and gene therapy production is driving unprecedented levels of outsourcing to contract manufacturing organizations. More than 65% of the manufacturing process for cell and gene therapies is outsourced, compared to approximately 35% for traditional biologics. This trend reflects the technical expertise, specialized infrastructure, and regulatory compliance capabilities that CMOs provide to smaller biotechnology companies.

Small biotechnology firms, which drive approximately two-thirds of innovation in the cell and gene therapy space, often lack the capacity, expertise, and resources for internal manufacturing capabilities. Outsourcing provides these companies with competitive advantages in terms of experience, cost efficiency, and accelerated time-to-market for their therapeutic candidates. The constantly growing clinical pipeline and increasing complexity of manufacturing requirements continue to reinforce this outsourcing trend across the industry.

Growing Clinical Trial Pipeline Is Propelling Manufacturing Demand

The exponential growth in cell and gene therapy clinical trials represents the primary driver propelling the need for manufacturing services. Currently, over 1,500 ongoing clinical trials for cell and gene therapies are registered with ClinicalTrials.gov, with 90% in Phase 1 and 2 trials. This robust pipeline indicates substantial future demand for commercial-scale manufacturing capabilities as therapies advance through development stages.

More than 360 clinical trials focusing specifically on CAR-T cell therapies alone are underway, highlighting the concentrated investment in cellular immunotherapy development. The increasing success rates in early-phase trials are driving confidence among pharmaceutical companies to advance their programs, creating sustained demand for manufacturing services throughout the product lifecycle. This clinical momentum is particularly strong in oncology applications, where breakthrough therapies are demonstrating unprecedented efficacy in previously untreatable conditions.

High Manufacturing Cost Acts as a Market Restraint

On average, it can cost companies anywhere from USD 1 to 5 billion to develop a single cell or gene therapy. The high cost of manufacturing remains one of the most significant barriers to the growth and scalability of the cell and gene therapy (CGT) manufacturing market. Unlike traditional pharmaceuticals, CGTs involve intricate, labor-intensive, and customized production processes. This complexity results in exceptionally high capital and operational expenditure, making it challenging for manufacturers to achieve cost-efficiency and profitability, especially at early commercial stages.

Further contributing to the cost burden is the reliance on single-use technologies and the need for maintaining a sterile and controlled environment. Facilities must adhere to current Good Manufacturing Practices (cGMP) and invest heavily in contamination control, cleanroom maintenance, and environmental monitoring.

Regulatory Approvals and Supportive Policies Offer Opportunities

Favorable regulatory environments and expedited approval pathways are significantly accelerating market development across major global markets. The U.S. FDA has approved more than 20 cell and gene therapies over the past two decades, with plans to approve up to 20 products annually starting from 2025. These regulatory successes are building investor confidence and stimulating substantial investments in manufacturing infrastructure and technology development.

Government initiatives are further supporting market expansion through targeted funding and policy frameworks. The U.S. Department of Health and Human Services launched the Cell and Gene Therapy Access Model in January 2025, inviting drug manufacturers to provide access to cell and gene therapy products at lower prices. Similarly, the Government of Canada invested around USD 2.2 billion from 2020 to 2024 to strengthen domestic biomanufacturing capabilities, demonstrating a strong governmental commitment to advancing this therapeutic sector.

Cell and Gene Therapy Manufacturing Services Market Segmentation and Category Analysis

Therapy Type Analysis

Cell therapy dominates the manufacturing services market with a substantial share of 65% in 2024, driven by the increasing number of products entering the marketplace and extensive clinical trial activity. The prevalence of cell therapy manufacturing services reflects the advanced development stage of cellular therapeutics, particularly CAR-T cell therapies and other cell-based immunotherapies. Over 360 clinical trials focusing on CAR-T cell therapies alone demonstrate the significant investment in cellular therapy development and the corresponding demand for specialized manufacturing capabilities.

Gene therapy is expected to register the higher CAGR during 2025–2032, fueled by breakthrough approvals and technological advancements in viral vector production. The gene therapy category benefits from increasing investments in production process improvements and enhanced manufacturing capabilities. Substantial investments of around USD 2.3 billion in gene therapies over the past decade indicate strong industry commitment to advancing gene therapy manufacturing capabilities and commercial viability.

Based on therapy type, the market has the following categories:

• Cell (Larger Category)
• Gene (Faster-Growing Category)

Indication Analysis

Cancer commands the largest market share of 55% in 2024, reflecting the concentrated focus on cancer treatments where cell and gene therapies have demonstrated the most significant clinical success. The oncology category benefits from numerous approved CAR-T cell therapies and a robust pipeline of investigational treatments targeting various cancer types. Cell and gene therapies offer promising approaches in cancer treatment by targeting precise molecular pathways, bolstering immune system responses to tumors, and directly eradicating cancer cells. Almost 10 million people die each year of cancer, says the World Health Organization.

Central nervous system disorders represent the fastest-growing indication category during the forecast period, driven by breakthrough therapies addressing previously untreatable neurological conditions. Advances in gene editing technologies such as CRISPR and improved delivery mechanisms are opening new treatment possibilities for genetic neurological disorders. The pressing need to address neurological conditions with limited treatment options is driving substantial investment in developing and manufacturing innovative cell and gene therapy interventions. As per studies, up to 300 million new CNS disease cases are diagnosed each year.

Based on indication, the market has the following categories:

• Cancer (Largest Category)
• Cardiovascular Diseases
• Orthopedic Diseases
• Ophthalmic Diseases
• Central Nervous System Diseases (Fastest-Growing Category)
• Infectious Diseases
• Others

Application Analysis

Commercial manufacturing held the larger market share, of 75% in 2024, reflecting the increasing number of approved therapies transitioning from clinical development to market commercialization. The commercial manufacturing category benefits from the growing pipeline of late-stage therapeutic candidates approaching regulatory approval and the expanding market penetration of existing approved products. Major market players are undertaking strategic initiatives to meet growing commercial demand, including capacity expansion and technology upgrades.

Clinical manufacturing is expected to witness the higher CAGR during the forecast period, driven by the exponential growth in clinical trial activity across all therapeutic areas. With over 1,975 clinical trials currently underway globally, the demand for clinical-scale manufacturing services continues to accelerate. The expanding clinical pipeline, particularly in Phase 1 and 2 trials, requires specialized manufacturing capabilities to support diverse study protocols and regulatory requirements.

Based on application, the market has the following categories:

• Clinical Manufacturing (Faster-Growing Category)
• Commercial Manufacturing (Larger-Category)

End User Analysis

Pharmaceutical & biotechnology companies dominate the market with 55% share in 2024, attributed to their significant investments in research and development and extensive expertise in drug discovery and development. These companies are the primary drivers of cell and gene therapy innovation, leveraging their resources to advance promising therapeutic candidates from preclinical stages through clinical trials to commercialization. Large biopharmaceutical companies are making substantial investments in cell and gene therapy programs and manufacturing capabilities. As per studies, pharma & biotech companies spend up to USD 900 billion annually on research, development, and manufacturing.

Academic & research institutes represent the fastest-growing end user category, reflecting the increasing collaboration between academic institutions and industry partners in advancing cell and gene therapy research. These institutions play crucial roles in fundamental research, early-stage development, and clinical trial execution. The substantial number of non-industry trials, which represented 36% of the trial starts in 2023, demonstrates the significant contribution of academic institutions to advancing the field.

Based on end user, the market has the following categories:

• Pharmaceutical & Biotechnology Companies (Larger Category)
• Academic & Research Institutes (Faster-Growing Category)

Mode Analysis

Contract manufacturing maintains the largest market share, of 70% in 2024, driven by increasing outsourcing of manufacturing activities by biotech and pharmaceutical companies to leverage specialized expertise and infrastructure. Contract manufacturing organizations specialize in providing comprehensive manufacturing services, including cell culture, viral vector production, process development, and manufacturing scale-up. The dynamic regulatory landscape and need for flexibility in manufacturing capacity further drive demand for contract manufacturing services. Studies predict global biopharma companies’ spending on CDMO services to reach USD 31.8 billion by 2030.

In-house manufacturing is projected to exhibit the highest CAGR of 16.7% during the forecast period as larger pharmaceutical companies build internal capabilities to maintain control over critical manufacturing processes. Building dedicated in-house manufacturing facilities provides companies with greater control over production timelines, quality standards, and intellectual property protection. However, the substantial capital investment required for in-house facilities often makes contract manufacturing more attractive for smaller biotechnology companies.

Based on mode, the market has the following categories:

• Contract (Larger Category)
• In-House (Faster-Growing Category)

Workflow Analysis

Process development captures the largest workflow share of 20% in 2024, driven by the critical need to optimize manufacturing processes as therapies transition from clinical trials to commercial production. The complexity of cell and gene therapy manufacturing requires extensive process development to ensure reproducibility, scalability, and regulatory compliance. Process development services are essential for establishing robust manufacturing methods that can support both clinical and commercial production requirements.

Vector production is expected to register the highest CAGR of 16.9% during the forecast period, reflecting the growing demand for gene therapy applications and viral vector-based delivery systems. The increasing number of gene therapy clinical trials and regulatory approvals is driving substantial investment in viral vector manufacturing capabilities. Advanced viral vector production technologies are critical for delivering genetic material effectively to target cells and tissues.

Based on workflow, the market has the following categories:

• Cell Processing
• Cell Banking
• Process Development (Largest Category)
• Fill & Finish Operations
• Analytical And Quality Testing
• Raw Material Testing
• Vector Production (Fastest-Growing Category)

Cell and Gene Therapy Manufacturing Services Market Regional Growth Dynamics

North America Cell Gene Therapy Manufacturing Services Market Size

North America held the largest market share, of 45%, in 2024, and it is expected to maintain its leadership position throughout the forecast period. The region's dominance is attributed to the high concentration of biopharmaceutical companies, advanced research and development capabilities, and strong governmental support for regenerative medicine initiatives. North America leads globally with more than 400 enterprises actively engaged in developing cell and gene therapy products for various disorders.

The U.S. FDA's expedited approval pathways for innovative therapies are accelerating the commercialization of cell and gene therapies, creating sustained demand for manufacturing services. The presence of numerous leading biotech firms and specialized contract manufacturing organizations provides advanced and scalable production capabilities that support the region's market leadership. Additionally, substantial funding from both private and public sectors has accelerated research and development activities, leading to a surge in clinical trials and product approvals.

The U.S. cell and gene therapy manufacturing services market is set to grow at a CAGR of 17.1% between 2025 and 2032, driven by robust technological infrastructure, significant biotechnology investment, and a highly skilled workforce. Major pharmaceutical companies are investing heavily in establishing and expanding manufacturing facilities across North America to meet growing commercial demand.

Asia Pacific Cell Gene Therapy Manufacturing Services Market Growth

Asia-Pacific is expected to record the fastest growth during the forecast period, with a CAGR of 17.5%, driven by rising research and development investments and strategic collaborations aimed at improving manufacturing capabilities. The region benefits from increasing governmental support, expanding healthcare infrastructure, and growing investment from both domestic and international companies seeking to establish manufacturing presence in key Asian markets.

China and Japan are emerging as key players in the regional market, with local companies partnering with global leaders to enhance production capacity and technological capabilities. The rapid expansion of clinical trial activity in the region is driving demand for both clinical and commercial manufacturing services. Lower manufacturing costs, skilled workforce availability, and improving regulatory frameworks are attracting international companies to establish operations in Asia-Pacific.

China's focus on CAR-T cell therapy and rising regulatory approvals are further propelling demand for manufacturing services during scale-up production. The region's growing emphasis on developing domestic biotechnology capabilities and reducing dependence on imported therapies is driving substantial investment in local manufacturing infrastructure.

Based on geography, the market has the following categories:

• North America (Largest Regional Market)
  • U.S. (Larger Country Market)
  • Canada (Faster-Growing Country Market)
• Europe
  • Germany (Largest-Country Market)
  • U.K.
  • France (Faster-Growing Country Market)
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific (Fastest-Growing Regional Market)
  • Japan
  • China (Largest Country Market)
  • India (Fastest-Growing Country Market)
  • South Korea
  • Australia
  • Rest of APAC
• Latin America
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Rest of LATAM
• Middle East and Africa
  • Saudi Arabia (Largest Country Market)
  • South Africa
  • U.A.E. (Fastest-Growing Country Market)
  • Rest of MEA

Cell and Gene Therapy Manufacturing Services Market Competitive Landscape

• The cell and gene therapy manufacturing services market is moderately consolidated, with several key players dominating significant market share, while numerous smaller specialized providers serve niche segments.
• The market benefits from the presence of established contract development and manufacturing organizations with extensive experience in biologics production, alongside emerging companies focused specifically on cell and gene therapy manufacturing capabilities.
• The top 10 key players collectively control approximately 70% of the total market share in 2024, indicating a consolidated market structure where established players maintain competitive advantages through scale, expertise, and regulatory compliance capabilities.
• Leading companies achieve their market positions through strategic investments in advanced manufacturing technologies, facility expansions, and comprehensive service offerings that span the entire product development lifecycle.
• Recent strategic initiatives demonstrate the industry's focus on capacity expansion and technological advancement to meet growing demand.
• Major players are undertaking facility expansions, technology upgrades, and strategic acquisitions to enhance their manufacturing capabilities and geographic reach.
• The increasing complexity of cell and gene therapy production requires specialized expertise in viral vector manufacturing, cell culture optimization, and quality control systems that favor established industry leaders.
• Key competitive strategies include partnerships with biotechnology companies, investments in automation and single-use technologies, and development of platform technologies that can support multiple therapeutic modalities.
• Companies are focusing on building integrated service offerings that provide end-to-end solutions from process development through commercial manufacturing and distribution.

Cell and Gene Therapy Manufacturing Services Market News

• September 2024, ScaleReady USA and Bio-Techne Corporation introduced G-Rex optimized ProPak GMP Cytokines for the efficient, closed-system manufacturing of cell and gene-modified cell therapies.
• July 2024, Genezen Laboratories Inc. announced an agreement to acquire uniQure's N.V.’s commercial gene therapy operations in Lexington, MA, bringing strategic manufacturing facilities and operational capabilities to the former's manufacturing network.
• January 2024, Kyowa Kirin Co. Ltd. completed the acquisition of Orchard Therapeutics plc, to meet the needs of patients with devastating genetic diseases where current treatment options are limited.
• December 2023, the FDA approved bluebird bio’s Lyfgenia and Vertex’s Casgevy cell-based gene therapies for sickle cell disease in patients aged 12 years and older.